TWTao Wang

Tao Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tao Wang has a total of 339 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Germline DDX41 defines a distinct subgroup in MDS undergoing transplantation with reduced relapse and improved survival

    by Nico Gagelmann, Christopher R. Reilly, Archana Sasi, Kyle Hebert, Paul Auer, Jing Dong, Tao Zhang, Tao Wang, Corey S. Cutler, Robert J. Soiffer, et al.

    Germline DDX41 variants are a recognized cause of adult myelodysplastic neoplasms (MDS), characterized by distinct biological features and favorable prognosis. The independent effect of DDX41 status on outcomes after allogeneic transplantation, the role of conditioning intensity, and treatment-related toxicity risk remain unresolved. To address this gap, we analyzed 1,514 patients with MDS undergoing transplantation prior to routine DDX41 testing alongside a wild-type comparator, providing an unbiased benchmark for this molecular subgroup. Forty-nine patients (3.2%) carried pathogenic/likely pathogenic (P/LP) germline DDX41 variants; 19 (39%) had an additional somatic DDX41 mutation, most commonly p.R525H. P/LP DDX41 cases were older (median 63 vs 59 years) and showed lower IPSS-M risk with absent TP53 mutations (0% vs 21%). In terms of outcome, 2-year relapse incidence was significantly lower in P/LP DDX41 (17% vs 34%, p=0.01). In multivariable analysis, the presence of a DDX41 P/LP variant independently associated with lower risk of relapse (hazard ratio 0.43, 95% CI 0.21-0.88; p=0.02), concentrated in the reduced-intensity/nonmyeloablative stratum. Adjusted models showed significantly improved disease-free survival (DFS) for P/LP DDX41 (hazard ratio 0.62, 95% CI 0.41-0.95; p=0.03) and no significant association with non-relapse mortality (NRM) or graft-versus-host disease (GVHD). In summary, these findings identify DDX41-associated MDS as a transplant subgroup with superior DFS regardless of conditioning intensity driven by reduced relapse risk and lack of excess NRM and GVHD supporting incorporation of germline DDX41 status into transplant planning.

  • Open Access

    Impact of age on graft-versus-host disease and overall survival in pediatric hematopoietic cell transplant recipients

    by Miki Nishitani, Rudi-Ann Graham, Tao Wang, Jakob Devos, Stephanie J. Lee, Stephen R. Spellman, Carrie L. Kitko, Margaret L. MacMillan, Zachariah DeFilipp, Ashley N. Gray, et al.

    Advances in graft-versus-host disease (GVHD) prevention and treatment have resulted in expanded donor options and improvement in treatment-related mortality (TRM). This analysis aimed to compare the incidence of acute and chronic GVHD (aGVHD and cGVHD, respectively) in pediatric patients by recipient age and to evaluate the impact of GVHD on overall survival (OS) and TRM. We included 14 099 patients aged ≤21 years who received their first allogeneic hematopoietic cell transplantation from 2002 to 2020, categorizing recipient age as 0 to 2 years (infants/toddlers), 3 to 12 years (school-aged), and 13 to 21 years (adolescent/young adult). There was no difference in grade 2 to 4 and 3 to 4 aGVHD by day 100 among age groups, except among patients with nonmalignant disease (NMD), among whom there was a small increase in incidence of severe aGVHD in older patients. Incidence of moderate/severe cGVHD by 1 year was higher with age. A similar impact of age was observed after adjusting for patient, donor, and transplant characteristics. Risk of severe aGVHD was higher in older children with NMD. Severe aGVHD and moderate/severe cGVHD were independently associated with inferior OS. In patients with malignant disease, both severe aGVHD and moderate/severe cGVHD were associated with increased risk of TRM. In conclusion, risk of moderate/severe cGVHD increases with recipient age, and risk of severe aGVHD is increased among older patients with nonmalignant conditions. Despite the low overall incidence of aGVHD and cGVHD in children, both are associated with significantly worse survival. These data highlight the need to consider GVHD outcomes at time of consultation and for improved prevention and treatment approaches.


  • Open Access

    Validated clinical risk score for acute graft-versus-host disease in adult allogeneic hematopoietic cell transplantation

    by Caden M. Ulschmid, Xiao Li, Tao Wang, Brent R. Logan, Joseph Pidala, Margaret L. MacMillan, Carrie L. Kitko, Stephanie J. Lee, Stephen R. Spellman, Wael Saber

    Acute graft-versus-host disease (aGVHD) contributes to significant morbidity after allogeneic hematopoietic cell transplantation (allo-HCT). We aimed to develop and validate a clinical score to identify patients with significantly different risk for developing aGVHD. Analysis included adults who underwent allo-HCT during 2008-2019. Eligibility criteria were widely inclusive of transplant indications, donor types, graft types, conditioning regimens, and GVHD prophylaxis regimens. The final cohort of 21 796 patients was randomly split into training and validation cohorts, with 15 258 (70%) and 6538 (30%) patients, respectively. The primary outcome was grade 2 to 4 aGVHD, and the secondary outcome was grade 3 to 4 aGVHD, by day 100 posttransplant. Risk scores were developed using the training cohort, tested using the validation cohort, and stratified into 4 percentile groups. The odds of grade 2 to 4 aGVHD by day 100 posttransplant were 1.50 (95% confidence interval [CI], 1.29-1.75; P< .0001) for the 25th to 50th percentile group, 2.0 (95% CI, 1.78-2.40; P< .0001) for the 50th to 75th percentile group, and 3.1 (95% CI, 2.72-3.65; P< .0001) for the >75th percentile group compared with the ≤25th percentile group in the validation cohort. The odds of grade 3 to 4 aGVHD by day 100 posttransplant were 1.4 (95% CI, 1.11-1.74; P = .0043) in the 25th to 50th percentile group, 2.0 (95% CI, 1.61-2.49; P< .0001) in the 50th to 75th percentile group, and 3.2 (95% CI, 2.64-3.98; P< .0001) in the >75th percentile group compared with the ≤25th percentile group in the validation cohort. Here, to our knowledge, we have developed the first validated, widely inclusive clinical risk score for the development of aGVHD after allo-HCT.


  • Higher HLA-DRB1 Evolutionary Divergence Is Associated with Reduced Relapse and Improved Survival after Matched Unrelated Hematopoietic Cell Transplantation

    by Jennifer N. Saultz, Yung-Tsi Bolon, Tao Wang, Stephen R. Spellman, Stephanie J. Lee, Meilun He, Christine Camacho-Bydume, Chirag Krishna, Diego Chowell, Brian C. Shaffer, et al.


  • Open Access

    Soluble urokinase plasminogen activator receptor and acute kidney injury in hematopoietic cell transplantation

    by Bhavna Bhasin-Chhabra, Tao Wang, John E. Levine, Shalini Shenoy, Miguel-Angel Perales, Asad Bashey, Hershel Raff, Wael Saber

    Acute kidney injury (AKI) frequently follows hematopoietic cell transplantation (HCT). Soluble urokinase-type plasminogen activator receptor (suPAR) is a biomarker of AKI in the general population. We evaluated suPAR and its association with AKI requiring dialysis (AKI-D) in patients undergoing allogeneic HCT (alloHCT). Performance of suPAR was compared with serum creatinine (sCr) and neutrophil gelatinase-associated lipocalin (NGAL). Data were obtained from the Blood and Marrow Transplant Clinical Trials Network 1202 cohort, an observational study of 1709 alloHCT recipients. Adults aged ≥18 years with AKI-D after HCT were included. Adults who did not develop AKI were included as controls and matched 1:1. Periodic serum samples (7-90 days) were analyzed for NGAL, suPAR, and sCr. The 1:1 matched case-control groups (n = 62 each) were balanced in demographic variables, except for graft-versus-host disease prophylaxis. The median time from transplant to AKI-D was 2.6 months (range, 0.03-20.39). The day +7 suPAR level after HCT was higher in patients with AKI (median, 2.7 ng/mL) than in controls (2.1 ng/mL; P = .002). In the multivariate analysis, the day +7 suPAR level was associated with the development of AKI-D (P = .009). The area under the curve for the receiver operating characteristic curve for day +7 suPAR levels was 0.75. Neither NGAL nor sCr were associated with AKI-D. Elevated day +7 suPAR levels predicted AKI and lower overall survival (OS). The suPAR level at day +7 after HCT may be an early prognostic factor for the development of AKI-D and OS. Future prospective studies could evaluate this at different stages of AKI. This trial was registered at www.ClinicalTrial.gov as #NCT01879072.


  • Novel Scoring System for Ranking Hematopoietic Stem Cell Transplantation

    by Lee Ann Baxter‐Lowe, Tao Wang, Michelle Kuxhausen, Stephen R. Spellman, Martin Maiers, Stephanie Lee, Jennifer Saultz, Esteban Arrieta‐Bolaños, Shahinaz M. Gadalla, Yung‐Tsi Bolon, et al.

    Background: When human leukocyte antigen (HLA)‐matched donors are not available for hematopoietic stem cell transplants (HSCT), there are no well‐accepted guidelines for ranking 7/8 HLA‐matched unrelated donors to achieve optimal transplant outcomes. A novel scoring system for ranking HLA mismatches for these donors was investigated.Methods: High‐resolution HLA types were used to determine amino acid mismatches located in the HLA antigen‐recognition domain. The location and physicochemical properties of mismatched amino acids were used to assign scores for peptide binding, T‐cell receptor docking, and HLA structure/function. The scores were tested using a cohort of 2319 patients with leukemia or myelodysplastic syndrome who received their first unrelated donor transplant using conventional graft‐versus‐host disease (GVHD) prophylaxis between 2000 and 2014. Donors were 7/8 HLA‐matched with a single HLA Class I mismatch. Primary outcomes were overall survival and acute GVHD.Results: The scores did not significantly (p < 0.01) associate with transplant outcomes, although a Peptide Score = 0 (i.e., no differences in peptide binding; N = 146, 6.3%) appears to have lower transplant‐related mortality (TRM) compared to higher scores (p = 0.019). HLA mismatches with Peptide Score = 0 were predominately HLA‐C*03:03/03:04 (62%), previously reported to be a permissive mismatch, and a group of 28 other HLA mismatches (38%) that showed similar associations with TRM.Conclusions: This study suggests that HLA mismatches that do not alter peptide binding or orientation (Peptide Score = 0) could expand the number of permissive HLA mismatches. Further investigation is needed to confirm this observation and to explore alternative scoring systems for ranking HLA mismatched donors.

  • Open Access

    Interplay between donor age and HLA-DP matching in 10/10 HLA-matched unrelated donor HCT

    by Rohtesh S. Mehta, Effie W. Petersdorf, Tao Wang, Stephen R. Spellman, Stephanie J. Lee

    In 10/10 HLA-matched unrelated donor (MUD) hematopoietic cell transplantation (HCT) with calcineurin-inhibitor (CNI)-based prophylaxis, T-cell epitope DP-matched and permissive mismatched donors are associated with similar overall survival (OS) whereas donors with nonpermissive mismatches should be avoided. Younger unrelated donors are also favored over older donors. We explored outcomes associated with different combinations of DP-matching and donor age (dichotomized at 35 years) to further guide donor selection. Using a Center for International Blood and Marrow Transplant Research data set, we categorized 10 783 patients into 6 groups: DP-matched/younger donor (n = 1591), DP-matched/older donor (n = 526), permissive-mismatched/younger donor (n = 3845), permissive-mismatched/older donor (n = 1184), nonpermissive mismatched/younger donor (n = 2659), and nonpermissive mismatched/older donor (n = 978). We noted that younger donor age, rather than DP matching, was associated with better OS. Younger donors with permissive mismatches were associated with improved OS compared with older matched donors. Furthermore, younger donors with nonpermissive mismatches were associated with improved OS compared with older donors with permissive mismatches. Our study adds further information about the association of DP matching and donor age with HCT outcomes. Donor age should be prioritized over DP matching in patients undergoing 10/10 HLA-MUD with CNI prophylaxis. Among those with younger donors, permissive-mismatched or DP-matched donors are preferred over nonpermissive mismatched donors.


  • Open Access

    Racial, ethnic, and socioeconomic diversity and outcomes of patients with graft-versus-host disease: a CIBMTR analysis

    by Nosha Farhadfar, Nahid Rashid, Karen Chen, Jakob D DeVos, Tao Wang, Karen Kuhn Ballen, Amer Beitinjaneh, Vijaya Raj Bhatt, Betty K. Hamilton, Peiman Hematti, et al.

    Socioeconomic status (SES) and race/ethnicity have been associated with the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HCT). Certain aspects of graft-versus-host disease (GVHD) management, such as the need for long-term care, prolonged immunosuppressive treatment, and close follow-up for complications, may exacerbate disparities. Adults (≥18 years) reported to the Center for International Blood and Marrow Transplant Research who underwent a first allo-HCT for acute leukemia, myelodysplastic syndrome, or myeloproliferative neoplasm between 2008 and 2018 were included. End points for those developing GVHD included overall survival (OS), transplant-related mortality (TRM), and disease relapse. Models were adjusted for patient- and transplant-related variables. A 2-sided P value < .01 was considered significant. Among the 14 825 allo-HCT recipients, 6259 (42.2%) and 6675 (45.0%) patients developed acute GVHD (aGVHD) and chronic GVHD (cGVHD), respectively. Among patients with aGVHD, non-Hispanic Black patients had increased TRM and overall mortality compared with non-Hispanic White patients; this association disappeared when severity of aGVHD was included in the model. Lower SES was associated with increased risk of disease relapse but not OS or TRM. In patients who developed cGVHD, race and ethnicity were not associated with OS, TRM, or disease relapse. However, the highest quartile of annual household income (≥$80 000) had improved OS and reduced TRM compared with the lowest quartile, after adjusting for race and ethnicity. In summary, race/ethnicity and SES are associated with outcomes after GVHD. Optimizing the health care resources available to low SES patients and strategies to minimize the risk of severe GVHD in non-Hispanic Black patients may improve long-term outcomes.


  • Open Access

    Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation

    by Karen Ballen, Tao Wang, Naya He, Jennifer M. Knight, Sanghee Hong, Haydar Frangoul, Leo F. Verdonck, Amir Steinberg, Miguel A. Diaz, C. Fred LeMaistre, et al.


  • Open Access

    Clinical Outcomes and Treatment Patterns in Adults With FLT3-ITDmut+ Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the United States and Canada

    by Bhavik J. Pandya, Linda J. Burns, Tao Wang, Bin Xie, Maelys Touya, James Spalding, Alana Block, Gaston Kuperman, Christopher Young